Name: Gadodiamide
Type: small molecule
Groups: approved
Indication: For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
Accession Number: DB00225 ( APRD00990)
Description: Gadodiamide is a gadolinium based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan. [Wikipedia]
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Omniscansolution287 mgintravenous25-03-1997Canada
Omniscaninjection287 mg/mLintravenous19-04-2002US
Omniscaninjection287 mg/mLintravenous29-07-2005US
Omniscan Liq IV 287mg/mlliquid287 mgintravenous31-12-199430-07-1997Canada

Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
Omniscan Liq IV 287mg/mlGadodiamide

  • No Category


Indication: For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
Pharmacodynamics: Not Available
Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, gadodiamide shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, gadodiamide primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadodiamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadodiamide in lesions such as neoplasms, abscesses, and subacute infarcts.
Absorption: Not Available
Volume of distribution:
  • 200 ± 61 mL/kg

Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Gadodiamide is eliminated primarily in the urine.
Half life: Two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively.
Clearance: Not Available
Toxicity: Not Available
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available


  • Ge healthcare

Dosage forms
Injectionintravenous287 mg/mL
Solutionintravenous287 mg
Liquidintravenous287 mg

Unit descriptionCostUnit
Omniscan 287 mg/ml bottle$6.49ml
Omniscan 287 mg/ml vial$6.98ml
Omniscan prefill plus syringe$7.02ml

CountryPatent NumberApprovedExpires (estimated)
5362475United States1994-11-082011-11-08
5560903United States1993-10-012013-10-01


Drug Interactions

Food Interactions:
  • Not Available


Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Alpha amino acids
  • Carbonyl compounds
  • Carboxylic acid salts
  • Carboxylic acids
  • Hydrocarbon derivatives
  • Organic salts
  • Organic zwitterions
  • Secondary carboxylic acid amides
  • Trialkylamines
  • Tricarboxylic acids and derivatives

  • Aliphatic acyclic compound
  • Alpha-amino acid
  • Alpha-amino acid amide
  • Amine
  • Carbonyl group
  • Carboxamide group
  • Carboxylic acid
  • Carboxylic acid amide
  • Carboxylic acid salt
  • Hydrocarbon derivative
  • Organic salt
  • Organic zwitterion
  • Organonitrogen compound
  • Organooxygen compound
  • Secondary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Tricarboxylic acid or derivatives


Synthesis Reference: Not Available
General Reference: Not Available
External Links:

ATC Codes:
  • Array

AHFS Codes:
  • 92:00.00

MSDS: Download

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.


The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.


Log in with your credentials

Forgot your details?